Protein posttranslational modifications (PTMs) refer to the breaking or generation of covalent
bonds on the backbones or amino acid side chains of proteins and expand the diversity of …

Protein S‐palmitoylation (hereinafter referred to as protein palmitoylation) is a reversible
lipid posttranslational modification catalyzed by the zinc finger DHHC‐type containing …

FMS-like tyrosine kinase 3 (FLT3) mutations occur in almost 30% of acute myeloid leukemia
(AML) patients. Despite the initial clinical efficacy of FLT3 inhibitors, many treated AML …

The internal tandem duplication of the juxtamembrane domain of the FMS-like tyrosine
kinase 3 (FLT3-ITD) is the most common genetic change in acute myeloid leukemia (AML) …

Mitochondria-associated endoplasmic reticulum membranes (MAMs) are dynamic coupling
structures between mitochondria and the endoplasmic reticulum (ER). As a new subcellular …

RAS mutations are among the most prevalent oncogenic drivers in cancers. RAS proteins
propagate signals only when associated with cellular membranes as a consequence of lipid …

FMS-like tyrosine kinase 3 (FLT3) is mutated in approximately 30% of acute myeloid
leukemia (AML) patients. The presence of FLT3-ITD (internal tandem duplication, 20–25%) …

Posttranslational modifications increase the complexity and functional diversity of proteins in
response to complex external stimuli and internal changes. Among these, protein lipidations …

Acute myeloid leukemia (AML) patients carrying Fms-like tyrosine kinase 3-internal tandem
duplication (FLT3-ITD) mutations often face a poor prognosis. While some FLT3 inhibitors …

EGFR tyrosine kinase inhibitors (TKIs) have transformed the treatment of EGFR-mutated non-
small cell lung carcinoma (NSCLC); however, therapeutic resistance remains a clinical …